(CNN) -- The race to develop an effective treatment or vaccine against Ebola is on as the largest outbreak in history continues to spread in West Africa. Meanwhile, questions about whether unproven treatments are appropriate to use, and who should get them, are inspiring passion and resentment.
On Wednesday, an Iowa-based company called NewLink said it has enough doses of an experimental Ebola vaccine to begin clinical trials in the next few weeks, if such trials are approved. Meanwhile, a shipment of 800 to 1,000 doses of the vaccine, known as VSV-EBOV, were delivered to health officials in Liberia, as a donation from the Public Health Agency of Canada.
reuters.com - By David Morgan and Sharon Begley - August 7, 2014
(Reuters) - The Obama administration is forming a special Ebola working group to consider setting policy for the potential use of experimental drugs to help the hundreds infected by the deadly disease in West Africa, U.S. officials said on Thursday.
The group is being formed under Dr. Nicole Lurie, Assistant Secretary for Preparedness and Response at the Department of Health and Human Services, an administration official said.
The action follows mounting international pressure as the death toll mounts to consider using untested treatments.
The move comes after the World Health Organization decided it was ethical in the circumstances to offer untested drugs to people infected by the virus.
The Canadian government has only around 1,500 doses of the vaccine, which it invented a few years ago. It has been effective in animals but has never been tested on humans.
A made-in-Canada experimental Ebola vaccine will be offered for use in the West African outbreak response, the Public Health Agency of Canada revealed Tuesday.
The news comes hours after the World Health Organization said a panel of experts advised that it would be ethical to use untested drugs and vaccines in this raging epidemic, which is several times larger than any previous outbreak.
A Spanish priest who contracted Ebola while working in Liberia has died in hospital, health authorities in Madrid have confirmed. Father Miguel Pajares (75) was the first European infected by a strain of the virus that has killed more than 1,000 people in West Africa.
He was airlifted from Liberia on August 7th after becoming infected while working for a non-governmental organisation there.
He was flown to Spain for treatment with his co-worker Juliana Bohi, a nun who has since tested negative for the disease.
The World Health Organization declared Tuesday that it's ethical to use unproven Ebola drugs and vaccines in the outbreak in West Africa provided the right conditions are met.
"In the particular circumstances of this outbreak and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention," the agency said in a statement.
The panel said "more detailed analysis and discussion" are needed to decide how to achieve fair distribution in communities and among countries, since there is an extremely limited supply of the experimental drugs and vaccines.
The statement from the UN health agency came amid a worldwide debate over the medical ethics surrounding the Ebola outbreak. However the agency sidestepped the key questions of who should get the limited drugs and how that should be decided.
WHO says 1,013 people have died so far in the Ebola outbreak in West Africa and authorities have recorded 1,848 suspected or confirmed cases.
(CNN) -- The government of Liberia says that sample doses of the experimental Ebola drug ZMapp will be sent there to treat doctors who have contracted the deadly virus.
The White House and Food and Drug Administration approved the Liberian request for the drug to be made available to them.
Liberia identified itself as the recipient of the drug after the company that makes ZMapp said earlier that its supply was exhausted after fulfilling the request of a West African country, which it did not name.
Recent Comments